150 related articles for article (PubMed ID: 32978942)
21. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
22. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
Han YM; Seo HJ; Choi SH; Jung YJ; Ahn SY; Yoo HS; Sung SI; Shim JW; Lee YK; Ko SY; Shin SM; Hwang JH; Lee JH; Choi BM; Kim ES; Jeon JH; Kim SS; Chang YS; Park WS
J Korean Med Sci; 2015 Jul; 30(7):924-31. PubMed ID: 26130956
[TBL] [Abstract][Full Text] [Related]
23. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
[TBL] [Abstract][Full Text] [Related]
24. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
Zylbersztejn A; Almossawi O; Gudka N; Tompsett D; De Stavola B; Standing JF; Smyth R; Hardelid P
Br J Clin Pharmacol; 2022 Mar; 88(3):1246-1257. PubMed ID: 34478568
[TBL] [Abstract][Full Text] [Related]
25. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
26. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
27. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
[TBL] [Abstract][Full Text] [Related]
28. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
30. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
31. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
33. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
Figueras-Aloy J; Carbonell-Estrany X; Quero J;
Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
[TBL] [Abstract][Full Text] [Related]
34. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
Law BJ; Langley JM; Allen U; Paes B; Lee DS; Mitchell I; Sampalis J; Walti H; Robinson J; O'Brien K; Majaesic C; Caouette G; Frenette L; Le Saux N; Simmons B; Moisiuk S; Sankaran K; Ojah C; Singh AJ; Lebel MH; Bacheyie GS; Onyett H; Michaliszyn A; Manzi P; Parison D
Pediatr Infect Dis J; 2004 Sep; 23(9):806-14. PubMed ID: 15361717
[TBL] [Abstract][Full Text] [Related]
35. Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.
Benítez-Guerra D; Piña-Flores C; Zamora-López M; Escalante-Padrón F; Lima-Rogel V; González-Ortiz AM; Guevara-Tovar M; Bernal-Silva S; Benito-Cruz B; Castillo-Martínez F; Martínez-Rodríguez LE; Ramírez-Ojeda V; Tello-Martínez N; Lomelí-Valdez R; Salto-Quintana J; Cadena-Mota S; Noyola DE
Influenza Other Respir Viruses; 2020 Mar; 14(2):182-188. PubMed ID: 31917902
[TBL] [Abstract][Full Text] [Related]
36. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
Krilov LR; Fergie J; Goldstein M; Brannman L
Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.
Anderson EJ; Carosone-Link P; Yogev R; Yi J; Simões EAF
Pediatr Infect Dis J; 2017 Aug; 36(8):699-704. PubMed ID: 28709160
[TBL] [Abstract][Full Text] [Related]
38. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
[TBL] [Abstract][Full Text] [Related]
39. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.
Liese JG; Grill E; Fischer B; Roeckl-Wiedmann I; Carr D; Belohradsky BH;
Eur J Pediatr; 2003 Apr; 162(4):230-6. PubMed ID: 12647195
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
